Please try another search
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants. The company was founded in 2012 and is headquartered in London, the United Kingdom.
Name | Age | Since | Title |
---|---|---|---|
Alan Edmund Walts | 62 | 2021 | Board Observer & Business Advisor |
Peter Redmond | 74 | 2015 | Independent Non-Executive Director |
Alexander Tarakhovsky | - | - | Scientific Advisor |
H. Michael Shepard | 73 | 2018 | Member of Scientific Advisory Board |
Marc Feldmann | - | 2017 | Independent Chairman & Chairman of Advisory Board |
Alexis M. Sandler | - | 2017 | Independent Co-Founder & Non-Executive Director |
Vladislav Sandler | - | 2013 | Co-Founder, CEO & Director |
Koen Van Besien | - | 2022 | Clinical Advisor & Medical Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review